Phase 1 Dose Escalation and Cohort Expansion Study Evaluating Safety, PK, PD and Clinical Activity of STC-15, a METTL3 Inhibitor in Patients with Advanced Malignancies, June 2024, ASCO Annual Meeting 2024

Justin C Moser¹, Kyriakos P Papadopoulos², Jordi Rodon Ahnert³, Yaara Ofir-Rosenfeld⁴, Josefin-Beate Holz⁴, STC15-22101 Study Team

¹HonorHealth Research Institute; ²START San Antonio; ³The University of Texas MD Anderson Cancer Center; ⁴Storm Therapeutics LTD